ReviewWorld journal of clinical oncology2021
Relationship between Th17 immune response and cancer.
Review in World journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 68 citations in OpenAlex.
- Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.Genes and immunity · 2026Article
- CCL20-CCR6 axis in autoimmune disease and cancer progression: clinical and therapeutic implications.Cell communication and signaling : CCS · 2026Review
- Metabolic profiling and systems biology analysis of Flammulina filiformis Fv19 extract: an integrated computational and experimental approach for dual anti-cancer and immunomodulatory therapy.BMC biotechnology · 2026Article
- Pro- and Anti-tumorigenic Effects of MSC Secretome in Glioblastoma: Mechanisms and Therapeutic Implications.Stem cell reviews and reports · 2026Review
- Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
- T-helper Transcription Factor Profiling in Peripheral Blood Mononuclear Cells: A Non-invasive Approach to Predicting Disease Stage in Breast Cancer.Biochemical genetics · 2026Article
- Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes.Journal for immunotherapy of cancer · 2026Article
- Probiotics Mixture, Prohep: a Potential Adjuvant for Low-Dose Sorafenib in Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma Suppression Through Modulating Gut Microbiota.Probiotics and antimicrobial proteins · 2026Article
- Deciphering Candida's Genomic Influence on Oral Squamous Cell Carcinoma: A Bioinformatics Approach.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Review
- Exosomal regulation of cellular reprogramming and polarization in the tumor microenvironment.Cancer cell international · 2025Review
- Association Between Tumor-Infiltrating Immune Cells and Early Recurrence in Ampulla of Vater Carcinoma.Cureus · 2025Article
- Regulatory dynamics of Th17 lymphocytes in oral squamous cell carcinoma: immune modulation and emerging immunotherapies.Immunologic research · 2025Review
- TWEAK/Fn14 Drives Tumor Progression and Is Associated With Poor Survival of Colorectal Liver Metastases With Replacement Growth Patterns.Cancer medicine · 2025Article
- A New Method of Canine CD4International journal of molecular sciences · 2025Article
- The Bidirectional Interplay between T Cell-Based Immunotherapies and the Tumor Microenvironment.Cancer immunology research · 2025Review
- Microenvironment-based immunotherapy in oral cancer: a comprehensive review.Medical oncology (Northwood, London, England) · 2025Review
- Exploring radiation resistance-related genes in pancreatic cancer and their impact on patient prognosis and treatment.Frontiers in immunology · 2025Article
- Review
- The expression of autophagy-related gene CXCL12 in endometriosis associated ovarian cancer and pan-cancer analysis.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the second leading cause of death worldwide and epidemiological projections predict growing cancer mortality rates in the next decades. Cancer has a close relationship with the immune system and, although Th17 cells are known to play roles in the immune response against microorganisms and in autoimmunity, studies have emphasized their roles in cancer pathogenesis. The Th17 immune response profile is involved in several types of cancer including urogenital, respiratory, gastrointestinal, and skin cancers. This type of immune response exerts pro and antitumor functions through several mechanisms, depending on the context of each tumor, including the protumor angiogenesis and exhaustion of T cells and the antitumor recruitment of T cells and neutrophils to the tumor microenvironment. Among other factors, the paradoxical behavior of Th17 cells in this setting has been attributed to its plasticity potential, which makes possible their conversion into other types of T cells such as Th17/Treg and Th17/Th1 cells. Interleukin (IL)-17 stands out among Th17-related cytokines since it modulates pathways and interacts with other cell profiles in the tumor microenvironment, which allow Th17 cells to prevail in tumors. Moreover, the IL-17 is able to mediate pro and antitumor processes that influence the development and progression of various cancers, being associated with variable clinical outcomes. The understanding of the relationship between the Th17 immune response and cancer as well as the singularities of carcinogenic processes in each type of tumor is crucial for the identification of new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.